Stay updated with breaking news from Accelerate Access. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Aurobindo and Viatris will manufacture in India; Cipla will manufacture in India and has plans to manufacture in South Africa as well.
UNAIDS welcomes the announcement by Medicines Patent Pool (MPP) and ViiV of three licenses signed with generic manufacturers Aurobindo, Cipla and Viatris for long-acting Cabotegravir for PrEP (Pre-exposure prophylaxis.) PrEP reduces risk of HIV transmission from sex or injecting drug use. UNAIDS also called for urgent action by ViiV to be taken to reduce the price and increase
RAHWAY, N.J.--(BUSINESS WIRE)--$MRK #MRK--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that LAGEVRIO™ (molnupiravir) did not demonstrate a statistically significant reduction in the risk of COVID-19 following household exposure to another individual with COVID-19. The Phase 3...
21.02.2023 - Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that LAGEVRIO (molnupiravir) did not demonstrate a statistically significant reduction in the risk of COVID-19 following household exposure to another individual ...
Investegate announcements from Marigold, Marigold™Announces Enhanced Partner Ecosystem